Allogene Therapeutics, Inc. (ALLO) Operating cash flow 2018–2025
Allogene Therapeutics, Inc. (ALLO) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$149.2MFY2025 · since FY2018: -$44.7M → -$149.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$149.2M | +25.5% |
| FY2024 | -$200.3M | +15.7% |
| FY2023 | -$237.7M | -7.8% |
| FY2022 | -$220.5M | -19.3% |
| FY2021 | -$184.8M | -60.6% |
| FY2020 | -$115.1M | +16.2% |
| FY2019 | -$137.3M | -207.6% |
| FY2018 | -$44.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALLO financial trends
ALLO RevenueALLO Net incomeALLO Net marginALLO Gross profitALLO Gross marginALLO Operating incomeALLO Operating marginALLO Free cash flowALLO Capital expendituresALLO Return on equityALLO Stock buybacksALLO Dividends paidALLO Total assetsALLO Total liabilitiesALLO Shareholders’ equityALLO overview →